ID   ZR-75-1 shWDR12-4
AC   CVCL_YJ29
DR   cancercelllines; CVCL_YJ29
DR   Wikidata; Q98136608
RX   CelloPub=CLPUB00550;
CC   Population: Caucasian.
CC   Doubling time: 23-37 hours (CelloPub=CLPUB00550).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): CelloPub=CLPUB00550
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9
ST   D16S539: 11
ST   D5S818: 13
ST   D7S820: 10,11
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 7
//
RX   CelloPub=CLPUB00550;
RA   Benhamron S.;
RT   "Validating WDR12 as a potential drug target in triple negative breast
RT   cancer.";
RL   Thesis MSc (2019), University of Toronto, Canada.
//